XM does not provide services to residents of the United States of America.

Edwards to sell critical care products unit to Becton Dickinson for $4.2 bln



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>UPDATE 3-Edwards to sell critical care products unit to Becton Dickinson for $4.2 bln</title></head><body>

Adds analyst comment in paragraph 3 and background paragraph 4 onwards

By Pratik Jain

June 3 (Reuters) -Edwards Lifesciences EW.N on Monday said it has agreed to sell its critical care products unit to Becton Dickinson BDX.N in an all-cash deal valued at $4.2 billion to sharpen focus on its heart devices business.

Edwards is no longer pursuing theplanned spin-off of thecritical care unit, which develops and sells advanced blood and heart monitoring systems that are used in surgical and intensive care settings, announced in April.

"The transaction creates a pure-play structural heart company positioning Edwards for strategic initiatives that could further create shareholder value," RBC Capital Markets analyst Shagun Singh said in a note.

California-based Edwards has been facing fierce competition for its Transcatheter aortic valve replacement (TAVR) devices, the company's lead product. These devices are usedto perform minimally invasive surgery for people with heart valve disease.

Edwards intends to use the after-tax cash proceeds to expand opportunities for its heart devices and invest in new technologies.

The unit, which generated $928 million in revenue last year, also sells other patient monitoring products, sensors and catheters, as well as predictive software and apps.

Becton Dickinson said the deal was consistent with the company's 2025 M&A strategy, which seeks "growth-enhancing and value-creating tuck-ins."

The buyout is expected to be immediately accretive to all key financial measures, including Becton Dickinson's revenue growth, and adjusted earnings per share, it added.

New Jersey-based Becton expects to fund the all-cash transaction with about $1 billion of cash and $3.2 billion of new debt.

The transaction is expected to close by the end of 2024, subject to the satisfaction or waiver of certain closing conditions.

Shares of Edwards were up 1.6%, while Becton rose about 3% in early morning trade following announcement.



Reporting by Pratik Jain in Bengaluru; Editing by Tasim Zahid

</body></html>

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.